Da Volterra, a late-stage biopharmaceutical company developing novel intestinal microbiome-protective therapies, announced today that it has significantly strengthened its patents portfolio with 3 new patents granted: 2 of which in the United States and 1 in Japan.
These new patents cover optimized beta-lactamase enzymes capable of inactivating a large scope of antibiotics with unprecedented efficacy and stability. The enzymes will be further optimized and used in innovative therapeutic strategies developed by Da Volterra.
“Continued recognition from major patent offices worldwide validates the breadth of Da Volterra’s technology. These latest acknowledgments are significant as they open the way to new developments by the team to address major unmet medical needs such as to combat the rise of carbapenem resistance which often starts in the gut microbiome” commented Pierre-Alain Bandinelli, Chief Strategy Officer of Da Volterra.
These patents further reinforce Da Volterra’s position as a leader in the microbiome space with multiple complementary approaches of microbiome protection that the company will be able to exploit in exclusivity.